Abiopharma

HNI CORP (HNI) Reports the reporting period Financial Results HNI CORP (HNI) announced its financial results for the period ending the reporting period. Key Financial Highlights:

• Revenue: $1347
• Net Income: (0.55)
• EPS: 0.40
• Cash and equivalents: $64
  • expected in 2026
  • expected in both segments•Cost management — including the termination and reprioritization of projects at Steelcase, synergy recognition, and legacy network optimization savings will offset lower volume growth expectations and continued investment•The Corporation expects to deliver a fifth straight year of double-digit non-GAAP EPS growth in 2026